The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
AIMS: To determine the effects of glucagon-like peptide-1 receptor agonists compared with placebo and other anti-diabetic agents on weight loss in overweight or obese patients with type 2 diabetes mellitus. METHODS: Electronic searches were conducted for randomised controlled trials that compared a glucagon-like peptide-1 receptor agonist therapy at a clinically relevant dose with a comparator treatment (other type 2 diabetes treatment or placebo) in adults with type 2 diabetes and a mean body mass index ≥ 25 kg/m2. Pair-wise meta-analyses and mixed treatment comparisons were conducted to examine the difference in weight change at six months between the glucagon-like peptide-1 receptor agonists and each comparator. RESULTS: In the mixed treatment comparison (27 trials), the glucagon-like peptide-1 receptor agonists were the most successful in terms of weight loss; exenatide 2 mg/week: -1.62 kg (95% CrI: -2.95 kg, -0.30 kg), exenatide 20 μg: -1.37 kg (95% CI: -222 kg, -0.52 kg), liraglutide 1.2 mg: -1.01 kg (95%CrI: -2.41 kg, 0.38 kg) and liraglutide 1.8 mg: -1.51 kg (95% CI: -2.67 kg, -0.37 kg) compared with placebo. There were no differences between the GLP-1 receptor agonists in terms of weight loss. CONCLUSIONS: This review provides evidence that glucagon-like peptide-1 receptor agonist therapies are associated with weight loss in overweight or obese patients with type 2 diabetes with no difference in weight loss seen between the different types of GLP-1 receptor agonists assessed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1 analogues also induce weight loss, which is associated with improved T2D prognosis.252,262,263”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [263]
In the citing paper
“GLP-1 analogues are also consistently more effective at inducing weight loss than most oral glucose-lowering drugs and insulin.262,263”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [263]
In the citing paper
“GLP-1 receptor agonists have a positive effect on weight loss in T2DM and do not show a negative effect on muscle mass.”
From Dionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis (2025) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
General methods for monitoring convergence of iterative simulations
Brooks, S. P., & Gelman, A. (1998) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.1998.10474787 · Cited by 6,045
Levesque, R. J. R. (2017) · Encyclopedia of Adolescence · doi:10.1007/978-3-319-32132-5_447-2 · Cited by 4,021
Peters, J. L., Sutton, A. J., Jones, D. R., Abrams, K. R., & Rushton, L. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.010 · Cited by 2,053 · cited 1×
“Publication bias was assessed visually using contour enhanced funnel plots [12] for all comparisons that contained five or more studies.”
MethodDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 1×
“4 Pharmaceutical Buse (2009) [43] Exenatide 20μg Austria, Denmark, Finland, France, Germany, Ireland, Macedonia, Norway, Poland, Puerto Rico, Romania, Slovenia, Spain, Sweden, Switzerland, USA 231 6 32.”
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · cited 1×
“1 59 36 Pharmaceutical Buse (2004) [9] Exenatide 20μg USA 125 6.”
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 1×
“A random effects mixed treatment comparison meta-analysis was conducted using a linear regression model adjusting for the fact that some trials had more than two treatment arms [13].”
MethodNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Cited by
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Martin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Davies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506
Self-citationReed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Htike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12849 · Cited by 416
Self-citationSemaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00070 · Cited by 412
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Hinnen, D. (2017) · Diabetes Spectrum · doi:10.2337/ds16-0026 · Cited by 394
“5 kg), with no significant differences among these three treatments (24).”
BackgroundNahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323
“Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists has been shown to improve glycemic control (13), delay gastric emptying, and induce weight loss in people with type 2 diabetes (14,15).”
BackgroundEmerging role of SGLT-2 inhibitors for the treatment of obesity
Pereira, M. J., & Eriksson, J. W. (2019) · Drugs · doi:10.1007/s40265-019-1057-0 · Cited by 342
Ambery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30726-8 · Cited by 298
Therapeutic pipeline in nonalcoholic steatohepatitis
Vuppalanchi, R., Noureddin, M., Alkhouri, N., & Sanyal, A. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00408-y · Cited by 278
Henderson, S. J., Konkar, A., Hornigold, D. C., Trevaskis, J. L., Jackson, R., Fritsch Fredin, M., Jansson‐Löfmark, R., Naylor, J., Rossi, A., Bednarek, M. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12735 · Cited by 240
Drug therapy in obesity: a review of current and emerging treatments
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00816-y · Cited by 195
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171
Tillner, J., Posch, M. G., Wagner, F., Teichert, L., Hijazi, Y., Einig, C., Keil, S., Haack, T., Wagner, M., Bossart, M., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13494 · Cited by 164
RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Madhu, S., Chawla, R., Makkar, B., Ghosh, S., Saboo, B., & Kalra, S. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_225_20 · Cited by 167
“[637] Use of GLP-1receptor agonists,[254] SGLT-2 inhibitors,[255,638] and to some extents DPP-4 inhibitors[257,258] have been shown to induce weight loss and should be considered as add-on to metformin in obese T2DM patients.”
BackgroundCornell, S. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13230 · Cited by 156
Moiz, A., Filion, K. B., Toutounchi, H., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-01590 · Cited by 149
“Previous systematic reviews and meta-analyses of RCTs have examined the ef fi cacy and safety of GLP-1 RAs for weight loss in people with overweight or obesity, both with diabetes (46 – 48) and without diabetes (1, 49 – 51).”
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Pouwels, P. J. W., Pieters-van den Bos, I. C., Hoekstra, T., Diamant, M., van Raalte, D. H., & Cahen, D. L. (2016) · Diabetologia · doi:10.1007/s00125-016-4100-7 · Cited by 142
Dawed, A. Y., Mari, A., Brown, A., McDonald, T. J., Li, L., Wang, S., Hong, M.-G., Sharma, S., Robertson, N. R., Mahajan, A., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00340-0 · Cited by 131
Adipose Tissue Dysfunction and Obesity-Related Male Hypogonadism
Genchi, V. A., Rossi, E., Lauriola, C., D’Oria, R., Palma, G., Borrelli, A., Caccioppoli, C., Giorgino, F., & Cignarelli, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158194 · Cited by 175
RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017
Bajaj, S. (2018) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-018-0604-7 · Cited by 159
Lundkvist, P., Sjöström, C. D., Amini, S., Pereira, M. J., Johnsson, E., & Eriksson, J. W. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12779 · Cited by 108
Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency
Alavi, S. E., Cabot, P. J., & Moyle, P. M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00308 · Cited by 102
Tan, Q., Orsso, C. E., Deehan, E. C., Triador, L., Field, C. J., Tun, H. M., Han, J. C., Müller, T. D., & Haqq, A. M. (2019) · Obesity Reviews · doi:10.1111/obr.12992 · Cited by 103
“However, human studies assessing the effects of GLP-1 receptor agonists showed clinically relevant but only modest reduction in body weight.(148,149) In addition, GLP-1 receptor agonists are associated with”
BackgroundModern pharmacological treatment of obese patients
May, M., Schindler, C., & Engeli, S. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819897527 · Cited by 111
Castellana, M., Cignarelli, A., Brescia, F., Perrini, S., Natalicchio, A., Laviola, L., & Giorgino, F. (2019) · Scientific Reports · doi:10.1038/s41598-019-55524-w · Cited by 94
Castellana, M., Cignarelli, A., Brescia, F., Laviola, L., & Giorgino, F. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3082 · Cited by 84
“7 kg/year, while GLP‐1RA reportedly promotes weight loss, and one of them, liraglutide, is also approved for the treatment of obesity.(32,33) This meta‐analysis confirms that both”
BackgroundHuman Genetics of Obesity and Type 2 Diabetes Mellitus: Past, Present, and Future
Ingelsson, E., & McCarthy, M. I. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002090 · Cited by 95
Lingvay, I., Hansen, T., Macura, S., Marre, M., Nauck, M. A., de la Rosa, R., Woo, V., Yildirim, E., & Wilding, J. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001706 · Cited by 71
“6 In addition to managing glucose levels, GLP-1RAs also reduce BW, 7 34 35 and this potential for weight loss has been reflected by the GLP-1RA liraglutide (3.0 mg once daily) gaining approval as a treat-ment for obesity.”
InfluentialGLP-1 receptor agonists in NAFLD
Petit, J.-M., & Vergès, B. L. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30070-8 · Cited by 76
Vosoughi, K., Salman Roghani, R., & Camilleri, M. (2022) · Obesity Medicine · doi:10.1016/j.obmed.2022.100456 · Cited by 65
Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes
Mirabelli, M., Chiefari, E., Caroleo, P., Arcidiacono, B., Corigliano, D. M., Giuliano, S., Brunetti, F. S., Tanyolaç, S., Foti, D. P., Puccio, L., et al. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17010207 · Cited by 61
“In this view, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), by providing an additional benefit of weight loss [9], would represent a preferable second-line option for patients with obesity and inadequately controlled diabetes, as adjunct to lifestyle interventions and metformin [10].”
BackgroundPreiss, D., Dawed, A. Y., Welsh, P. I., Heggie, A. J., Jones, A. G., Dekker, J., Koivula, R. W., Hansen, T. H., Stewart, C., Holman, R. R., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12826 · Cited by 61
Sloan, L. A. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12969 · Cited by 58
Pradhan, R., Yin, H., Yu, O. H. Y., & Azoulay, L. (2022) · Diabetes Care · doi:10.2337/dc21-1953 · Cited by 62
“First, these drugs are known to induce weight loss (15,16).”
BackgroundBusch, R. S., & Kane, M. P. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1342509 · Cited by 63
Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis
Wang, M., Li, L., Xu, Y., Du, J., & Ling, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.958428 · Cited by 69
Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo
Frémaux, J., Venin, C., Mauran, L., Zimmer, R., Guichard, G., & Goudreau, S. R. (2019) · Nature Communications · doi:10.1038/s41467-019-08793-y · Cited by 60
Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
Noureddin, M., Muthiah, M. D., & Sanyal, A. J. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.105 · Cited by 55
Compare And Contrast the Glucagon-like Peptide-1 Receptor Agonists (GLP1RAs)
Latif, W. A., Lambrinos, K. J., & Rodríguez, R. (2021) · StatPearls · Cited by 119
Monami, M., Zannoni, S., Pala, L., Silverii, G. A., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.163 · Cited by 47
“The improvement of glucose control [14] and of other risk factors, such as blood pressure, body weight and lipid profile [15,16], could play a major role.”
BackgroundPharmacological Treatment for Obesity in Adults: An Umbrella Review
Khalil, H., Ellwood, L., Lord, H., & Fernandez, R. S. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028019898912 · Cited by 54
“The critical appraisal tools/instruments used in the reviews were Cochrane,(14,19,20,24) Jadad scale,(15) Verhagen Delphi list,(22) and other “validated scales” (Table 1).(21,23,25) Weight change was the most frequently reported outcome.”
BackgroundMethodResultInfluentialNovel dual incretin agonist peptide with antidiabetic and neuroprotective potential
Pathak, N. M., Pathak, V., Gault, V. A., McClean, S., Irwin, N., & Flatt, P. R. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.021 · Cited by 43
Patoulias, D., Doumas, M. N., Kotsis, V., Stavropoulos, K., Imprialos, K. P., Zografou, I., Petidis, K., Bakatselos, S., & Karagiannis, A. I. (2020) · Current Diabetes Reviews · doi:10.2174/1573399815666190614141918 · Cited by 53
GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review
Pantazopoulos, D., Gouveri, E., Papazoglou, D., & Παπάνας, Ν. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112924 · Cited by 53
Vergès, B. L., & Charbonnel, B. H. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30067-8 · Cited by 44
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
Chawla, R., Madhu, S. V., Makkar, B. M., Ghosh, S. K., Saboo, B., Kalra, S., & On behalf of RSSDI-ESI Consensus Group (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00819-2 · Cited by 57
Dulaglutide for the treatment of type 2 diabetes
Scheen, A. J. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1296131 · Cited by 48
Weight-centric treatment of type 2 diabetes mellitus
Ghusn, W., Hurtado, M. D., & Acosta, A. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100045 · Cited by 40
“In patients with and without T2DM, several systematic reviews and meta-analyses associated the use of GLP-1 agonists with signi fi cant weight loss in a dose-dependent manner [88 – 92].”
BackgroundKotecha, P., Huang, W., Yeh, Y.-Y., Narvaez, V. M., Adirika, D., Tang, H., Bernier, A. V., WESTEN, S. C., Smith, S. M., Bian, J., et al. (2025) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2025.3243 · Cited by 58
Witham, M. D., Granic, A., Pearson, E. R., Robinson, S. M., & Sayer, A. A. (2023) · Drugs & Aging · doi:10.1007/s40266-023-01042-4 · Cited by 49
“In patients with T2DM, GLP-1 receptor agonists cause significant weight loss [139] – an action often viewed as beneficial, as many patients with T2DM have obesity.”
BackgroundGLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side
Dieter, B. P., Alicic, R. Z., & Tuttle, K. R. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00211.2018 · Cited by 38
“Third, GLP-1 receptor agonists promote weight loss of 3 kg on average compared with other treatments for hyperglycemia in type 2 diabetes (27, 41).”
BackgroundGLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials
Jia, X., Alam, M., Ye, Y., Bajaj, M., & Birnbaum, Y. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6773-2 · Cited by 40
Mirabelli, M., CHIEFARI, E. D., Tocci, V., Caroleo, P., Giuliano, S., Greco, E. A., Luque, R. M., Puccio, L., FOTI, D. P., Aversa, A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10050985 · Cited by 39
“In addition, GLP-1 RAs have been shown to promote satiety signals and delay gastric emptying, thus reducing postprandial glycemic and insulinemic peaks, while favoring weight loss [5].”
BackgroundIncretin drugs as modulators of atherosclerosis
Gallego-Colon, E., Wojakowski, W., & Francuz, T. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.011 · Cited by 35
Wysham, C., Rosenstock, J., Vetter, M. L., Dong, F., Öhman, P., & Iqbal, N. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13056 · Cited by 38
Overgaard, R. V., Lindberg, S. Ø., & Thielke, D. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13479 · Cited by 34
“All were conducted in subjects with T2DM.”
BackgroundInfluentialLi, Y., He, J., Lyu, X., Yuan, Y., Wang, G., & Zhao, B. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.10.071 · Cited by 35
“from clinical trials have revealed that EXT treatment not only improves glycemic control but also results in sustainable weight loss in EXTtreated type 2 diabetic subjects (Potts et al., 2015).”
Cracking the combination: Gut hormones for the treatment of obesity and diabetes
Alexiadou, K., Anyiam, O., & Tan, T. (2019) · Journal of Neuroendocrinology · doi:10.1111/jne.12664 · Cited by 34
Wang, X., Ding, Z., Yang, F., Dai, Y., Chen, P., Theus, S. A., Singh, S. P., Budhiraja, M., & Mehta, J. L. (2016) · Clinical Science · doi:10.1042/cs20160061 · Cited by 33
Sasaki, A., Yokote, K., Naitoh, T., Fujikura, J., Hayashi, K., Hirota, Y., Inagaki, N., Ishigaki, Y., Kasama, K., Kikkawa, E., et al. (2021) · Diabetology International · doi:10.1007/s13340-021-00551-0 · Cited by 41
Schneider, E. L., Hearn, B. R., Pfaff, S. J., Reid, R. R., Parkes, D. G., Vrang, N., Ashley, G. W., & Santi, D. V. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00218 · Cited by 32
Pereira, M. J., Lundkvist, P., Kamble, P. G., Lau, J., Martins, J. G., Sjöström, C. D., Schnecke, V., Walentinsson, A., JOHNSSON, E. K., & Eriksson, J. W. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0449-6 · Cited by 32
Sharma, R., Wilkinson, L., Vražić, H., Popoff, E., Lopes, S. H. K., Kanters, S., & Druyts, E. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1476332 · Cited by 35
Use of Glucose-Lowering Agents in Diabetes and CKD
Alicic, R. Z., Neumiller, J. J., Galindo, R. J., & Tuttle, K. R. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.09.018 · Cited by 38
Kunutsor, S. K., & Seidu, S. (2025) · Drugs · doi:10.1007/s40265-025-02263-0 · Cited by 44
“Early studies noted modest reductions in body weight—typically 2% to 5%—among patients with T2D [77], which prompted further investigation into whether higher doses of GLP-1RAs could elicit greater weight loss in individuals with overweight or obesity, particularly in the absence of diabetes [78].”
Wang, Z., Hou, L., Huang, L., Guo, J., & Zhou, X. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.03.010 · Cited by 29
Bensignor, M. O., Bomberg, E. M., Bramante, C. T., Divyalasya, T. V. S., Hale, P. M., Ramesh, C. K., Rudser, K. D., & Kelly, A. S. (2021) · Pediatric Obesity · doi:10.1111/ijpo.12778 · Cited by 34
Dulaglutide (LY-2189265) for the treatment of type 2 diabetes
Scheen, A. J. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1141046 · Cited by 28
Philis‐Tsimikas, A., Wysham, C., Hardy, E., Han, J., & Iqbal, N. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.11.012 · Cited by 26
van Schaik, J., Begijn, D. G. A., van Iersel, L., Vergeer, Y., Hoving, E. W., Peeters, B., & van Santen, H. M. (2020) · Obesity Facts · doi:10.1159/000509302 · Cited by 25
The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis
Yugar, L. B. T., Sedenho-Prado, L. G., da Silva Ferreira, I. M. C., Silva, C. A. M., Sposito, A. C., & Cercato, C. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01337-5 · Cited by 23
“The impact on HbA1c and body weight mirrors that observed in adults; however, these medications exhibit heightened efficacy in lowering fasting blood glucose in children [15, 16].”
BackgroundTandon, S., Ayis, S. A., Hopkins, D. L., Harding, S., & Stadler, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14221 · Cited by 32
“The weight-lowering effects of the GLP-1 receptor agonist liraglutide were consistent across all studies, which aligns well with the evidence base in type 2 diabetes.(74,75) Two studies reported weight loss related to total body fat,(40,41) which has previously been observed in obese individuals with type 2 diabetes.”
ResultHallaj, S., Halfpenny, W., Chuter, B., Weinreb, R. N., Baxter, S. L., & Cui, Q. N. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.08.030 · Cited by 29
Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists
Tommerdahl, K. L., Nadeau, K. J., & Bjornstad, P. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.06.001 · Cited by 29
Optimization of peptide-based polyagonists for treatment of diabetes and obesity
Knerr, P. J., Finan, B., Gelfanov, V. M., Pérez–Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.10.047 · Cited by 24
Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy
Khoo, B. C. E., & Tan, T. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0119 · Cited by 23
Ertuğlu, L. A., Porrini, E., Hornum, M., Demiray, A., Afşar, B., Ortíz, A., Covic, A. C., Rossing, P. R., & Kanbay, M. (2021) · Transplant International · doi:10.1111/tri.13883 · Cited by 26
Yousef, C. C., Thomas, A., Matar, M. A., Ghandoura, L., Aldossary, I., Almuhanna, S. M., Alhussain, F. H., Bisher, F. B. A., Aljohani, R. M., Balubaid, A. N., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108871 · Cited by 26
“In the systematic review and meta - analysis of RCTs conducted by Potts et al to evaluate the effect of GLP-1RAs on weight loss in T2DM, they found an average weight loss of (cid:1) 1.01 kg to (cid:1) 1.51 kg with liraglutide [28].”
BackgroundInfluentialMyeloid cells in retinal and brain degeneration
Guo, M., Schwartz, T. D., Dunaief, J. L., & Cui, Q. N. (2021) · FEBS Journal · doi:10.1111/febs.16177 · Cited by 27
Ren, X., Hua, H., Wu, Y., Zhang, W., Long, X., Bai, Y., & Cheng, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-09807-0 · Cited by 38
“Previous studies have shown that GLP-1RAs are effective in reducing body weight and blood pressure in comparison to placebo 84,85 .”
Dar, S., Tahrani, A. A., & Piya, M. K. (2015) · Practical Diabetes · doi:10.1002/pdi.1978 · Cited by 28
Li, X., Qie, S., Wang, X., Zheng, Y., Liu, Y., & Liu, G. (2018) · Endocrine · doi:10.1007/s12020-018-1708-z · Cited by 29
Willey, V. J., Kong, S. X., Wu, B., Raval, A. D., Hobbs, T. M., Windsheimer, A., Deshpande, G., Tunceli, O., Sakurada, B., & Bouchard, J. R. (2018) · Europe PMC (PubMed Central) · Cited by 31
Jung, C., & Mok, J. (2019) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2019.28.1.18 · Cited by 23
Dahlqvist, S., Ahlén, E., Filipsson, K., Gustafsson, T., Hirsch, I., Tuomilehto, J., Imberg, H., Bo, A., Attvall, S., & Lind, M. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000464 · Cited by 24
Ortiz, M. M. L., Garay‐Sevilla, M. E., Tejero, M. E., & Pérez-Luque, E. L. (2016) · British Journal Of Nutrition · doi:10.1017/s0007114516002798 · Cited by 21
“Indeed, previous studies have reported a positive effect of GLP-1 receptor agonists that led to weight loss in obese or overweight T2DM patients((27,28)).”
BackgroundSubcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes
Hedrington, M. S., Tsiskarishvili, A., & Davis, S. N. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1439014 · Cited by 23
Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review
Raza, F. A., Altaf, R., Bashir, T., Asghar, F., Altaf, R., Tousif, S., Goyal, A., Mohammed, A., Mohammad, M. F., Anan, M., et al. (2024) · Medicine · doi:10.1097/md.0000000000040364 · Cited by 37
“[106] Apovian et al [107] conducted a 24-week study in which participants with obesity and T2D were given exenatide in addition to a lifestyle modification program that included a 600 kcal/d deficit and at least 2.5 hours of increased physical activity per week.”
MethodInfluentialPetroni, M. L., Montesi, L., Colosimo, S., Caletti, M. T., Mazzotti, A., & Marchesini, G. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.82 · Cited by 19
Tuersun, A., Hou, G., & Cheng, G. (2024) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2024.07.011 · Cited by 20
New Agents for the Treatment of Type 2 Diabetes
Libianto, R., & Ekinci, E. I. (2019) · Critical Care Clinics · doi:10.1016/j.ccc.2018.11.007 · Cited by 19
Sotos‐Prieto, M., Smith, C. E., Lai, C., Tucker, K. L., Ordovás, J. M., & Mattei, J. (2019) · Journal of Nutrition · doi:10.1093/jn/nxz210 · Cited by 17
Jain, M., Carlson, G. F., Cook, W. J., Morrow, L., Petrone, M., White, N. E., Wang, T., Naylor, J., Ambery, P., Lee, C., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4789-6 · Cited by 18
Richardson, B., Khan, M. Q., Brown, S. A., Watt, K. D. S., & Izzy, M. J. (2021) · Hepatology Communications · doi:10.1002/hep4.1876 · Cited by 19
Kotsis, V., Jordan, J., Stabouli, S., Antza, C., Micić, D., Jelaković, B., Schlaich, M. P., Nilsson, P. M., Kreutz, R. H., Mancia, G., et al. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002279 · Cited by 15
Metadata
- Authors
- Potts, J. E., Gray, L. J., Brady, E. M., Khunti, K., Davies, M. J., & Bodicoat, D. H.
- Affiliations
- University of Leicester (GB)
- University Hospitals of Leicester NHS Trust (GB)
- Corresponding author
- Bodicoat, Danielle H.
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-06-29
- Volume
- 10
- Issue
- 6
- Pages
- e0126769
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4487255
- OpenAlex
- W1643809894
- Cited by
- 163
- References
- 44
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 10 · 2023: 10 · 2022: 12 · 2021: 17 · 2020: 19 · 2019: 17 · 2018: 29 · 2017: 20 · 2016: 11 · 2015: 4
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Keele Research Repository (Keele University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion, cc-by)
- Funders
- University Hospitals of Leicester NHS Trust
- National Institute for Health and Care Research
- University of Leicester
- Loughborough University
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- GLP-1 receptor agonists, weight loss, type 2 diabetes, obesity, exenatide, liraglutide, antidiabetic drugs
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Peptides, Venoms, Weight Loss, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.